POZEN Logo
Print Page   Close Window

Press Release

POZEN Inc. CEO to Present at The BIO CEO & Investor Conference

CHAPEL HILL, N.C., Feb 15, 2002 /PRNewswire-FirstCall via COMTEX/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of product candidates for the treatment of migraine, announced that John R. Plachetka, Pharm.D., the company's chairman, president and chief executive officer, will make a presentation to investors during the BIO CEO & Investor Conference. The presentation is scheduled for Thursday, February 21, 2002 at 8:50 a.m. EST at the Waldorf Astoria in New York City. The presentation will also be broadcast live through the Internet and will remain archived for 30 days. The webcast can be accessed through the POZEN website with the following URL:

http://www.corporate- ir.net/ireye/ir_site.zhtml?ticker=POZN&script=1020&item_id=w,600528,1

North Carolina-based POZEN Inc. is a pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. POZEN's initial focus is on developing products for migraine therapy, a global market expected to exceed $2.6 billion this year. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN."

POZEN is on the Internet at www.pozen.com .

CONTACT:
Matt Czajkowski
Chief Financial Officer, of POZEN
+1-919-913-1040
or
General Inquiries
Kathy Brunson of FRB Weber Shandwick
+1-312-640-6696